Key result
The OPTICARE XL cardiac rehabilitation program achieved a significantly greater short-term weight loss of 3.6 kg compared to 1.8 kg with standard care, though this benefit was not sustained long-term.
Why the study?
Patients with cardiac diseases and obesity do not benefit optimally from standard cardiac rehabilitation programs, as exercises and counselling do not adequately address their specific needs.
Does a dedicated 1-year cardiac rehabilitation program improve long-term weight loss, physical activity, and quality of life in obese patients with CAD or AF compared to standard cardiac rehabilitation?
Does a dedicated 1-year cardiac rehabilitation program improve long-term weight loss, physical activity, and quality of life in obese patients with CAD or AF compared to standard cardiac rehabilitation?
Answers are grounded in this paper and cite their sources.
A dedicated 1-year cardiac rehabilitation program for patients with obesity showed promising short-term weight loss but did not provide long-term added value over standard cardiac rehabilitation.
Obesity is a known and commonly encountered risk factor for the development of cardiac diseases. Patients with cardiac diseases who also have obesity do not benefit optimally from standard cardiac rehabilitation (CR) programs. Exercises performed during CR are not the best fit for patients with obesity and counselling sessions often do not address their specific needs. OPTICARE XL is the first large multicentre randomised controlled trial to investigate the added value of a dedicated one-year CR program specifically designed for patients with obesity and integrated in daily practice. The short-term effects on body weight and physical activity were promising and patients with obesity experienced the program as highly desirable. However, the OPTICARE XL CR program did not show long-term added value compared with standard CR on health-related quality of life, psychosocial well-being, body weight, physical activity and physical fitness, nor on costs. The current article offers an overview of the background of this trial and discusses the most important results of the OPTICARE XL trial and the reasons behind the unanticipated long-term outcomes. Furthermore, it offers recommendations for future research and how to redesign the OPTICARE XL CR program to expand the short-term results.
No takes yet. Share an insight, caveat, or question.
Uijl et al. (2023) conducted a review in Coronary artery disease or nonvalvular atrial fibrillation with obesity (n=201). OPTICARE XL CR program vs. Standard CR was evaluated on Weight loss at 3 months (p=0.002). The OPTICARE XL cardiac rehabilitation program achieved a significantly greater short-term weight loss of 3.6 kg compared to 1.8 kg with standard care, though this benefit was not sustained long-term.
Synapse has enriched 10 related papers. Consider them for comparative context: